Frédéric Joliot Institute for Life Sciences - Sur le même thème https://joliot.cea.fr/drf/joliot/en/Pages/news/Science/2019/Lassa-fever-vaccine.aspx Website of the Frédéric-Joliot Institute of Life Sciences which includes 4 departments: I2BC, DMTS, NeuroSpin and Service hospitalier Frédéric Joliot (SHFJ). The teams are mainly located at the CEA Paris-Saclay center and at the Orsay hospital. en-US https://www.cea.frhttps://www-cea-fr.admsite.extra.cea.fr/Style%20Library/Themes/drf/instituts/images/logo-cea-joliot.png Frédéric Joliot Institute for Life Sciences - Sur le même thème https://joliot.cea.fr/drf/joliot/en Functionalization of the B subunit of Shiga toxin as a vaccine tool https://www.cea.fr/drf/joliot/en/Pages/news/Science/2024/Functionalization-B-subunit-Shigatoxin-vaccine-tool.aspx Researchers at SIMoS (DMTS) describe the synthesis, engineering and evaluation of the properties of the B subunit of bacterial Shiga toxin (STxB), administered mucosally, as a vaccine tool. Their results confirm the value of using a synthetic STxB in an anti-tumor and anti-infectious vaccination strategy. Biotechnology ; Vaccine SIMOPRO Scientific result préclinique; Fri, 26 Jan 2024 11:00:00 GMT Salmonellosis and shigellosis: a monoclonal antibody induces cross-protection https://www.cea.fr/drf/joliot/en/Pages/news/Science/2021/Salmonellosis-shigellosis-monoclonal-Ab-cross-protection.aspx Researchers at CEA-Joliot (SPI unit in collaboration with SIMoS unit) have developed a monoclonal antibody directed against a common region of two proteins of the bacteria Shigella and Salmonella and capable of inducing cross-protection against infections caused by these bacteria. Bacteria ; Vaccine Researchers SIMOPRO Scientific result Antibody;IpaD-318;host cell;injectiosome; Thu, 25 Mar 2021 11:00:00 GMT Mapping of Ebola T-cell response: towards a new vaccine ? https://www.cea.fr/drf/joliot/en/Pages/news/Science/2020/Mapping-Ebola-T-cell-response.aspx SIMoS researchers, in collaboration with Genopole, Excellgene, Vaxeal holding SA (Switzerland), used a large-scale approach to map and characterize the response of CD4 T-cells from healthy donors, against two proteins from the Ebola-Zaire virus. They observed a strong response to the viral nucleoprotein (NP) and suggest that components of NP may be included in the design of new Ebola vaccines. Virus ; Vaccine Scientific result Wed, 24 Jun 2020 10:00:00 GMT Salmonellosis and shigellosis: first demonstration of cross-protection induced by virulence factors SipD and IpaD https://www.cea.fr/drf/joliot/en/Pages/news/Science/2020/Salmonella-shigella-cross-protection.aspx SPI researchers show for the first time, in a mouse model, the induction of cross-protection against Salmonella and Shigella infections, two pathogenic bacteria responsible for gastrointestinal diseases (typhoid, dysentery among others), one of the main causes of morbidity and mortality in several regions of Africa and Asia. Vaccine ; Bacteria Scientific result Mon, 22 Jun 2020 10:00:00 GMT How the identification of attenuated forms of the SARS-CoV-2 virus could help to control the current epidemic ? https://www.cea.fr/drf/joliot/en/Pages/news/Institute/2020/Identification-attenuated-covid-virus-variants.aspx An opinion article, published in Environmental Microbiology, and written by an international consortium initiated by three researchers of Joliot Institute, proposes an original way of research on Covid-19 through the identification by sequencing of attenuated variants of the SARS-CoV-2 virus in populations at risk with little or no symptoms. Virus ; Genomics ; Vaccine Tue, 12 May 2020 10:00:00 GMT Lassa fever: a vaccine soon to be tested. https://www.cea.fr/drf/joliot/en/Pages/news/Science/2019/Lassa-fever-vaccine.aspx Researchers from Pasteur Institute, in collaboration with seven research teams, including SPI (LI2D/Marcoule), developed and evaluated the efficacy of several vaccine candidates against the virus responsible for Lassa haemorrhagic fever, endemic in Western Africa. They identified one of them as being the most effective, likely to quickly enter clinical trials in humans. Results are published in the journal Science Translational Medicine. Vaccine Scientific result Wed, 09 Oct 2019 10:00:00 GMT Mass spectrometry for quality control of vaccines https://www.cea.fr/drf/joliot/en/Pages/news/Science/2018/spectrometry-quality-control-vaccines.aspx ​A SPI Research Team (LI2D, Marcoule), in collaboration with CIRAD and AU-PANVAC, proposes a new quality control technique for veterinary vaccines, based on very high resolution mass spectrometry. This strategy, based on the use of an ad hoc database to measure the proportion of antigens and contaminants in the vaccine preparation, will improve the quality control of vaccines against contagious caprine pleuropneumonia. Mass spectrometry ; Vaccine Scientific result Thu, 05 Jul 2018 10:00:00 GMT Toxins, vaccines, biobetters: a mission at the Butantan Institute of São Paulo https://www.cea.fr/drf/joliot/en/Pages/news/Institute/2018/Toxins-vaccines-biobetters-butantan.aspx ​​Last April, a delegation of experts from the DRF visited colleagues at the Butantan Institute of São Paulo, a biomedical research center that has had close links with several researchers at the Joliot Institute since 2014. This mission is is concluded by the signing of a framework agreement between the two institutes in the field of therapeutic and vaccine innovation. Institutional ; Toxicology ; Vaccine News Fri, 25 May 2018 10:00:00 GMT